Phase 1Recruiting
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Sponsored by Abramson Cancer Center at Penn Medicine
About this study
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Where this study is enrolling
- I'm interested
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Who can participate
Inclusion criteria
- ✓Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- ✓Prior exposure to at least 1 line of therapy
- ✓Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ✓ECOG PS 0-2
Exclusion criteria
- ✕Presence of a driver mutation that is susceptible to targeted therapy
- ✕No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
- ✕Other active invasive malignancy requiring ongoing therapy
- ✕Evidence of progressing or untreated brain metastases
- ✕Evidence or history of leptomeningeal disease
- ✕Uncontrolled tumor related pain
- ✕History of an autoimmune disease or IPF
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.